Showing results (771-780 of 1,188) with videos related to
Sort By:
Pageof 119
Blood|August 3, 2006
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaHagop Kantarjian, Yasuhiro Oki, Guillermo Garcia-Manero, et al.Leukemia & Lymphoma|November 10, 2017
Myeloid/lymphoid neoplasms with FGFR1 rearrangementPaolo Strati, Guilin Tang, Dzifa Y Duose, et al.Journal of Hematology & Oncology|January 5, 2019
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experienceKamal Chamoun, Hagop Kantarjian, Rami Atallah, et al.American Journal of Hematology|November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionElias Jabbour, Johannes Düll, Musa Yilmaz, et al.Cancer|September 23, 2016
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemiaFarhad Ravandi, Jeffrey Jorgensen, Gautam Borthakur, et al.Nature Genetics|March 17, 2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.American Journal of Hematology|January 5, 2017
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remissionNaveen Pemmaraju, Hagop Kantarjian, Jeffrey L Jorgensen, et al.Experimental Hematology|September 23, 2022
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaFaezeh Darbaniyan, Hong Zheng, Rashmi Kanagal-Shamanna, et al.Leukemia Research|January 31, 2021
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Faezeh Darbaniyan, Rashmi Kanagal-Shamanna, et al.American Journal of Hematology|September 2, 2022
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysisElias Jabbour, Koji Sasaki, Fadi G Haddad, et al.Pageof 119